K-BD Group (Korea Pharmaceutical and Bio Business Development Research Group, Chairman Lee Jae-hyeon) hosted a Promising Bio-Venture & Startup Investment Forum on the 15th. Twenty empresas with outstanding technological capabilities in areas such as rare disease new drugs, anticancer agents, drug delivery systems (DDS), and new drug target identification solutions participó to present their respective capabilities and I+D pipelines. The inversión forum continued through the 16th at KINTEX in Ilsan.
Senior Managing Director Kim Seunghoon declaró, "RCI001 ha completado the preclinical toxicology and DS (drug substance) stages, and a German company is programado to begin finished drug fabricación next month," adding, "We anticipate entering Phase 1 ensayo clínicos en el segundo semestre de este año, with the goal of entering FDA Phase 2 ensayo clínicos en el primer semestre de el próximo año."
